Derniers essais


EudraCT Number: 2022-003289-18 Sponsor Protocol Number: 219369 Start Date: 2023-05-08
Sponsor Name: GlaxoSmithKline Research & Development Limited
Full Title: A Phase 2, Single-Arm, Open-Label Study with Dostarlimab Monotherapy in Participants with Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer
Medical condition: Untreated Stage II/III dMMR/MSI-H locally advanced rectal cancer
Disease: Version SOC Term Classification Code Term Level
21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038049 Rectal cancer stage II PT
21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038050 Rectal cancer stage III PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing) IT (Ongoing) NL (Ongoing) ES (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-002470-86 Sponsor Protocol Number: 20190218 Start Date: 2023-05-08
Sponsor Name: Amgen Inc.
Full Title: A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without...
Medical condition: Overweight and Obesity
Disease: Version SOC Term Classification Code Term Level
20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
24.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing) HU (Ongoing) CZ (Ongoing) ES (Ongoing) PL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-003564-24 Sponsor Protocol Number: JAB-3312-1003 Start Date: 2023-05-05
Sponsor Name: Jacobio Pharmaceuticals Co., Ltd.
Full Title: A Phase 1/2a, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 Based Combination Therapies in Adult P...
Medical condition: Advanced Solid Tumors
Disease: Version SOC Term Classification Code Term Level
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: FR (Prematurely Ended)
Trial results: (No results available)

EudraCT Number: 2022-002650-48 Sponsor Protocol Number: UCDCRC/22/02 Start Date: 2023-05-05
Sponsor Name: University College Dublin
Full Title: The impact of Empagliflozin on Left atrIal Volume and the feasibility of using Fitbit and mHealth to prescribe Exercise in non-diabetic Pre- Heart Failure (ELIVE pre-HF Study)
Medical condition: pre-heart failure with preserved ejection fraction
Disease: Version SOC Term Classification Code Term Level
20.1 100000004849 10076396 Heart failure with preserved ejection fraction LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: IE (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-003865-39 Sponsor Protocol Number: WSG-AM12 Start Date: 2023-05-04
Sponsor Name: Westdeutsche Studiengruppe GmbH
Full Title: NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+pertuzumab in HER2+ early breast cancer
Medical condition: HER2+ early breast cancer
Disease: Version SOC Term Classification Code Term Level
20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006192 Breast cancer NOS LLT
23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
Population Age: Adults, Elderly Gender: Female
Trial protocol: DE (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-003951-41 Sponsor Protocol Number: BFS-AS-40184 Start Date: 2023-05-04
Sponsor Name: Teva Branded Pharmaceutical Products R&D, Inc.
Full Title: CONNected Electronic Inhalers Asthma Control Trial 3 (“CONNECT 3”), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison Study of Standard of Care Treatment Versus th...
Medical condition: Asthma
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: NL (Prematurely Ended)
Trial results: (No results available)
EudraCT Number: 2023-000033-33 Sponsor Protocol Number: 83631 Start Date: 2023-05-03
Sponsor Name: Maastricht University
Full Title: Short-term safety and efficacy of ketohexokinase inhibition in patients with hereditary fructose intolerance.
Medical condition: Hereditary fructose intolerance
Disease: Version SOC Term Classification Code Term Level
20.0 10010331 - Congenital, familial and genetic disorders 10019878 Hereditary fructose intolerance PT
20.1 10010331 - Congenital, familial and genetic disorders 10017397 Fructose intolerance hereditary LLT
21.0 10027433 - Metabolism and nutrition disorders 10072104 Fructose intolerance PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: NL (Completed)
Trial results: (No results available)

EudraCT Number: 2022-003056-14 Sponsor Protocol Number: VTX958-203 Start Date: 2023-05-03
Sponsor Name: Ventyx Biosciences, Inc
Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Patients with Active Psoriatic Arthritis
Medical condition: Active Psoriatic Arthritis
Disease: Version SOC Term Classification Code Term Level
21.0 100000004859 10037160 Psoriatic arthritis LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) BG (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-004411-11 Sponsor Protocol Number: NeoTreme Start Date: 2023-05-03
Sponsor Name: University Hospital Schleswig-Holstein, Campus Lübeck
Full Title: Phase 2 Study of Preoperative Gemcitabine Plus Cisplatin with Durvalumab (MEDI4736) and Tremelimumab in intrahepatic cholangiocarcinoma (NeoTreme)
Medical condition: Intrahepatic cholangiocarcinoma
Disease: Version SOC Term Classification Code Term Level
20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073077 Intrahepatic cholangiocarcinoma LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-003452-14 Sponsor Protocol Number: SBC007C401 Start Date: 2023-05-02
Sponsor Name: Berlin Cures GmbH
Full Title: A prospective, double-blind, randomised, parallel group, placebo controlled, multicentre, Phase II study to investigate the efficacy, GPCR autoantibody neutralising effect, safety, and tolerability...
Medical condition: long Covid
Disease: Version SOC Term Classification Code Term Level
25.1 10021881 - Infections and infestations 10087832 COVID-19 rebound LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing) ES (Ongoing) FI (Ongoing)
Trial results: (No results available)